COMPASS Pathways plc — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 76/100
What the filing says
COMPASS Pathways announced final NDA submission for COMP360 (psilocybin) will be filed within two weeks for treatment-resistant depression (TRD), with launch targeted for H1 2027 subject to FDA approval. Phase 3 data from COMP005 (52-week open label) and COMP006 (6-month) showed rapid onset and durability extending to one year with additional dosing; the company holds a National Priority Voucher potentially enabling 1–2 month FDA review. Cash position strengthened to $444.0M (vs. $149.6M at year-end 2025); 9M 2026 net loss was $172.4M vs. $194.0M in 9M 2025, with SG&A expenses rising to $72.6M (vs. $44.6M prior year) due to commercialization preparation across 8,500+ treatment centers. A late-stage PTSD trial is ongoing with VA collaboration.
Why this rating
NDA submission imminent and positive Phase 3 durability data substantially de-risk regulatory and clinical paths for a potential blockbuster in a $4M TRD market; H1 2027 launch assumption and $444M cash runway beyond 2028 are material. Relative to $257M market cap, this is a defining inflection. Execution risk remains.
Tradability signal
NO TRADE
No trade: positive news with only +2.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.39% over 4 hrs, n=285). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.00 ▲ 2.83% | at our read · unknown $8.75 | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved -2.76% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.